Login
$QTTB
$8.29 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role Joined 2025 pay Source
Jodie Morrison Also a director
Chief Executive Officer and Director
50 Since 2024
2 years
Not stated $1,558,870
Lee Kalowski
Chief Financial Officer and President
45 Since 2024
2 years
Not stated $987,147
Shelia Violette
Chief Scientific Officer and President of Research
65 Since 2024
2 years
2017 $774,446

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
9
serving now
Independent
7 of 9
stated in the proxy
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Mark Iwicki
Director Age On board Independent Committees Other public boards 2025 pay Source
Mark Iwicki
59 2024
2 years
Independent
Audit
Inhibikase Therapeutics, Inc. $229,443
Jodie Morrison
50 2024
2 years
Not independent None stated None stated Paid as CEO
Kathleen LaPorte
64 2024
2 years
Independent
Nominating and Corporate Governance
CERo Therapeutics Holdings, Inc. $184,096
Arthur Tzianabos
63 2016
10 years
Not independent
Research and Development
Stoke Therapeutics, Inc. Not stated
David Grayzel
58 2024
2 years
Independent
Research and Development
None stated $166,024
Isaac Manke
49 2024
2 years
Independent
Compensation
None stated Not stated
Diyong Xu
44 2024
2 years
Independent
Nominating and Corporate Governance
None stated $163,237
Bill Lundberg
62 2024
2 years
Independent
Compensation
None stated $179,500
Mary Thistle
66 2018
8 years
Independent
Audit
Atkis Oncology, Inc. $177,737

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 30, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support